Skip to main content
Livermore
Livermore
ZHEN

Commodore Capital LP

SEC CIK
0001831942
Latest filing
Aug 14, 2026

The latest 13F from Commodore Capital LP covers Q2 2026 (filed Aug 14, 2026): 33 long positions worth $1.68B. The top 10 holdings make up 68.2% of the portfolio, and the largest is Relay Therapeutics, Inc. (RLAY) at 13.4%. Livermore has 25 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
5
Est. +$121.5M
Added
6
Est. +$61.3M
Reduced
9
Est. −$491.3M
Sold out
8
Est. −$234.7M

Top 5 holdings

Share of this quarter's portfolio value

  1. RLAYRelay Therapeutics, Inc.
    13.4%$224.5MHistory
  2. ELVNEnliven Therapeutics, Inc.
    9.9%$166.2MHistory
  3. ALKSAlkermes plc.
    9.4%$157.2MHistory
  4. COGTCogent Biosciences, Inc.
    7.0%$118.0MHistory
  5. AMLXAmylyx Pharmaceuticals, Inc.
    6.0%$101.5MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. TNGXTango Therapeutics, Inc.
    +$70.3MNewHistory
  2. EDITEditas Medicine, Inc.
    +$28.8MNewHistory
  3. EYPTEyePoint, Inc.
    +$25.4MAddedHistory
  4. IFRXInflaRx N.V.
    +$16.4MNewHistory
  5. ASMBAssembly Biosciences, Inc.
    +$11.4MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. TNGXTango Therapeutics, Inc.
    +4.19 pp0.0% → 4.2%History
  2. EYPTEyePoint, Inc.
    +1.81 pp2.1% → 3.9%History
  3. EDITEditas Medicine, Inc.
    +1.72 pp0.0% → 1.7%History
  4. IFRXInflaRx N.V.
    +0.97 pp0.0% → 1.0%History
  5. ASMBAssembly Biosciences, Inc.
    +0.71 pp1.6% → 2.3%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. SYRESpyre Therapeutics, Inc.
    −$94.6MReducedHistory
  2. RLAYRelay Therapeutics, Inc.
    −$93.5MReducedHistory
  3. NUVLNuvalent, Inc.
    −$90.6MReducedHistory
  4. ALKSAlkermes plc.
    −$62.9MReducedHistory
  5. KYMRKymera Therapeutics, Inc.
    −$57.3MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NUVLNuvalent, Inc.
    −4.21 pp4.9% → 0.7%History
  2. ERASErasca, Inc.
    −2.97 pp3.0% → 0.0%History
  3. XENEXenon Pharmaceuticals Inc.
    −2.78 pp2.8% → 0.0%History
  4. NRIXNurix Therapeutics, Inc.
    −2.04 pp2.0% → 0.0%History
  5. CLDXCelldex Therapeutics, Inc.
    −1.96 pp4.9% → 3.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.68B
−$49.5M (−2.9%) vs. prior quarter
Positions
33
−3 vs. prior quarter
Top 10 concentration
68.2%
Top 10 as share of value
Turnover
10.7%
Q2 2026, one quarter
Average holding period
7.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.05B (Q3 2025)

Q1 2021: $251.0MQ2 2021: $287.0MQ3 2021: $379.3MQ4 2021: $431.8MQ1 2022: $447.7MQ2 2022: $473.0MQ3 2022: $621.9MQ4 2022: $663.5MQ1 2023: $656.8MQ2 2023: $889.8MQ3 2023: $855.5MQ4 2023: $1.14BQ1 2024: $1.50BQ2 2024: $1.47BQ3 2024: $1.60BQ4 2024: $1.36BQ1 2025: $1.36BQ2 2025: $1.42BQ3 2025: $2.05BQ4 2025: $1.50BQ1 2026: $1.73BQ2 2026: $1.68B
Q1 2021Q2 2026
13F filings of Commodore Capital LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202633$1.68BRLAYELVNALKSvs. Q1 2026SEC
Q1 2026May 15, 202636$1.73BRLAYALKSELVNvs. Q4 2025SEC
Q4 2025Feb 17, 202633$1.50BRLAYALKSTYRAvs. Q3 2025SEC
Q3 2025Nov 14, 202537$2.05BMRUSNUVLXENEvs. Q2 2025SEC
Q2 2025Aug 14, 202533$1.42BMRUSNUVLXENEvs. Q1 2025SEC
Q1 2025May 15, 202531$1.36BMRUSNUVLELVNvs. Q4 2024SEC
Q4 2024Feb 14, 202531$1.36BMRUSPCVXNUVLvs. Q3 2024SEC
Q3 2024Nov 14, 202436$1.60BMRUSVERAXENEvs. Q2 2024SEC
Q2 2024Aug 14, 202435$1.47BMRUSNUVLXENEvs. Q1 2024SEC
Q1 2024May 15, 202439$1.50BMRUSVERANUVLvs. Q4 2023SEC
Q4 2023Feb 14, 2024Amended32$1.14BMRUSXENENUVLvs. Q3 2023SEC
Q3 2023Nov 14, 202330$855.5MMRUSVERAXENEvs. Q2 2023SEC
Q2 2023Aug 14, 202326$889.8MMRUSVERAAKROvs. Q1 2023SEC
Q1 2023May 15, 202332$656.8MXENEVRDNMRUSvs. Q4 2022SEC
Q4 2022Feb 14, 202335$663.5MXENEVRDNCOGTvs. Q3 2022SEC
Q3 2022Nov 14, 202230$621.9MCOGTXENEVRDNvs. Q2 2022SEC
Q2 2022Aug 15, 202224$473.0MMRUSXENECOGTvs. Q1 2022SEC
Q1 2022May 16, 202227$447.7MMRUSACRSBellus Health Inc Newvs. Q4 2021SEC
Q4 2021Feb 14, 202225$431.8MISEEMRUSACRSvs. Q3 2021SEC
Q3 2021Nov 15, 202129$379.3MISEEACRSCYTKvs. Q2 2021SEC
Q2 2021Oct 14, 2021Amended29$287.0MACRSSTSACELCvs. Q1 2021SEC
Q1 2021Oct 14, 2021Amended31$251.0MACRSCCCCKURA–SEC

13D and 13G filings

Companies where Commodore Capital LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

22 companies, largest stake first.

Companies where Commodore Capital LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
EDITEditas Medicine, Inc.13G9.90%16.0M sharesNewJun 2, 20261 filingJun 2, 2026SEC
IKTInhibikase Therapeutics, Inc.13G/A9.90%14.1M shares–Oct 17, 20242 filingsMay 15, 2026SEC
CATXPerspective Therapeutics, Inc.13G9.90%11.9M shares–Apr 19, 20243 filingsFeb 9, 2026SEC
SABSSAB Biotherapeutics, Inc.13G/A9.90%8.95M shares0.00 ppfrom 9.90%Oct 16, 20234 filingsAug 14, 2026SEC
AVTXAvalo Therapeutics, Inc.13G9.90%5.72M sharesNewJun 18, 20261 filingJun 18, 2026SEC
VTGNVistagen Therapeutics, Inc.13G/A9.90%4.24M shares0.00 ppfrom 9.90%Apr 14, 20226 filingsAug 14, 2026SEC
ANTXAN2 Therapeutics, Inc.13G9.90%3.70M sharesNewMar 16, 20261 filingMar 16, 2026SEC
ANROAlto Neuroscience, Inc.13G/A9.90%3.59M shares0.00 ppfrom 9.90%Oct 27, 20253 filingsMay 15, 2026SEC
ASMBAssembly Biosciences, Inc.13G9.90%1.62M sharesNewAug 15, 20251 filingAug 15, 2025SEC
IMUXImmunic, Inc.13G/A9.90%1.51M shares0.00 ppfrom 9.90%Oct 21, 20225 filingsAug 14, 2026SEC
ELVNEnliven Therapeutics, Inc.13G/A7.70%4.80M shares−2.20 ppfrom 9.90%Oct 24, 20229 filingsMay 15, 2026SEC
IPSCCentury Therapeutics, Inc.13G7.10%13.0M sharesNewJan 16, 20261 filingJan 16, 2026SEC
LBRXLB Pharmaceuticals Inc13G/A6.80%1.97M shares+1.30 ppfrom 5.50%Sep 18, 20252 filingsMay 15, 2026SEC
PEPGPepGen Inc.13G/A6.50%4.47M shares+1.40 ppfrom 5.10%Mar 11, 20262 filingsMay 15, 2026SEC
RLAYRelay Therapeutics, Inc.13G/A5.50%12.0M shares−4.40 ppfrom 9.90%May 15, 20254 filingsAug 14, 2026SEC
RACDResearch Alliance Corp IV13G5.50%500.0K sharesNewJul 20, 20261 filingJul 20, 2026SEC
RACCResearch Alliance Corp III13G5.50%500.0K sharesNewMay 28, 20261 filingMay 28, 2026SEC
JTTTJATT III Acquisition Corp13G5.20%400.0K sharesNewSep 2, 20261 filingSep 2, 2026SEC
IFRXInflaRx N.V.13G5.10%7.47M sharesNewAug 17, 20261 filingAug 17, 2026SEC
AMLXAmylyx Pharmaceuticals, Inc.13G5.10%5.65M sharesNewNov 17, 20251 filingNov 17, 2025SEC
RLMDRelmada Therapeutics, Inc.13G5.10%5.51M sharesNewMay 4, 20261 filingMay 4, 2026SEC
EYPTEyePoint, Inc.13G5.10%4.25M sharesNewJun 3, 20261 filingJun 3, 2026SEC

Latest filings

154 filings on file made by Commodore Capital LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Commodore Capital LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
JTTTJATT III Acquisition CorpSep 2, 20264:21 PM ET13G5.20%400.0K sharesNewAug 26, 2026SEC
IFRXInflaRx N.V.Aug 17, 20264:34 PM ET13G5.10%7.47M sharesNewAug 10, 2026SEC
PALIPalisade Bio, Inc.Aug 14, 20264:38 PM ET13G/A0.00%0 shares−7.20 ppfrom 7.20%Below 5%Jun 30, 2026SEC
JATTJATT II Acquisition Corp.Aug 14, 20264:29 PM ET13G/A0.00%0 shares−6.40 ppfrom 6.40%Below 5%Jun 30, 2026SEC
IMUXImmunic, Inc.Aug 14, 20264:17 PM ET13G/A9.90%1.51M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
KPTIKaryopharm Therapeutics Inc.Aug 14, 20264:14 PM ET13G/A0.00%0 shares−9.90 ppfrom 9.90%Below 5%Jun 30, 2026SEC
RLAYRelay Therapeutics, Inc.Aug 14, 20264:11 PM ET13G/A5.50%12.0M shares−4.40 ppfrom 9.90%Jun 30, 2026SEC
SABSSAB Biotherapeutics, Inc.Aug 14, 20264:07 PM ET13G/A9.90%8.95M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
DFTXDefinium Therapeutics, Inc.Aug 14, 20264:07 PM ET13G/A1.80%2.41M shares−5.40 ppfrom 7.20%Below 5%Jun 30, 2026SEC
VTGNVistagen Therapeutics, Inc.Aug 14, 20264:04 PM ET13G/A9.90%4.24M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
RACDResearch Alliance Corp IVJul 20, 20264:22 PM ET13G5.50%500.0K sharesNewJul 13, 2026SEC
AVTXAvalo Therapeutics, Inc.Jun 18, 20264:29 PM ET13G9.90%5.72M sharesNewJun 11, 2026SEC
EYPTEyePoint, Inc.Jun 3, 20264:39 PM ET13G5.10%4.25M sharesNewMay 27, 2026SEC
EDITEditas Medicine, Inc.Jun 2, 20265:31 PM ET13G9.90%16.0M sharesNewMay 26, 2026SEC
RACCResearch Alliance Corp IIIMay 28, 20264:20 PM ET13G5.50%500.0K sharesNewMay 20, 2026SEC
ELVNEnliven Therapeutics, Inc.May 15, 20264:30 PM ET13G/A7.70%4.80M shares−2.20 ppfrom 9.90%Mar 31, 2026SEC
PEPGPepGen Inc.May 15, 20264:19 PM ET13G/A6.50%4.47M shares+1.40 ppfrom 5.10%Mar 31, 2026SEC
TYRATyra Biosciences, Inc.May 15, 20264:19 PM ET13G/A4.20%2.48M shares−2.10 ppfrom 6.30%Below 5%Mar 31, 2026SEC
PALIPalisade Bio, Inc.May 15, 20264:14 PM ET13G/A7.20%12.4M shares−2.70 ppfrom 9.90%Mar 31, 2026SEC
LBRXLB Pharmaceuticals IncMay 15, 20264:11 PM ET13G/A6.80%1.97M shares+1.30 ppfrom 5.50%Mar 31, 2026SEC